Amphastar P (AMPH)vsTeva Pharma Industries Ltd ADR (TEVA)
AMPH
Amphastar P
$29.37
+1.73%
HEALTHCARE · Cap: $1.22B
TEVA
Teva Pharma Industries Ltd ADR
$44.50
-4.34%
HEALTHCARE · Cap: $50.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 2210% more annual revenue ($17.23B vs $745.79M). AMPH leads profitability with a 13.3% profit margin vs 2.9%. TEVA appears more attractively valued with a PEG of 1.04. AMPH earns a higher WallStSmart Score of 65/100 (C+).
AMPH
Buy65
out of 100
Grade: C+
TEVA
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+28.3%
Fair Value
$39.87
Current Price
$29.37
$10.50 discount
Intrinsic value data unavailable for TEVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 135.1% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Large-cap with strong market position
Strong operational efficiency at 27.4%
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
ROE of 6.3% — below average capital efficiency
2.9% margin — thin
Premium valuation, high expectations priced in
Revenue declined 1.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : AMPH
The strongest argument for AMPH centers on EPS Growth, P/E Ratio, Price/Book.
Bull Case : TEVA
The strongest argument for TEVA centers on Market Cap, Operating Margin. PEG of 1.04 suggests the stock is reasonably priced for its growth.
Bear Case : AMPH
The primary concerns for AMPH are Market Cap, Piotroski F-Score, PEG Ratio.
Bear Case : TEVA
The primary concerns for TEVA are Return on Equity, Profit Margin, P/E Ratio. A P/E of 99.9x leaves little room for execution misses. Debt-to-equity of 2.13 is elevated, increasing financial risk.
Key Dynamics to Monitor
AMPH carries more volatility with a beta of 0.94 — expect wider price swings.
AMPH is growing revenue faster at 8.2% — sustainability is the question.
TEVA generates stronger free cash flow (121M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AMPH scores higher overall (65/100 vs 42/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amphastar P
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?